Menu
Anchored by our commitment to reimagine treatments for the most urgently needed and underserved neurological and psychiatric disorders, we are building a pipeline of neuromodulators that promote balance and control of the central nervous system.
Our pipeline targets key neurochemical processes that make the central nervous system so challenging to treat.
| |
PRECLINICAL | TOX STUDIES | IND FILED | PHASE 1 | PHASE 2 | PHASE 3 | COMMERCIAL |
|---|---|---|---|---|---|---|---|
| SYMJEPI (Anaphylaxis) |
|
||||||
| ZIMHI (Opioid Overdose) |
|
||||||
| DPI-125 (Opioid Use Disorder) |
|
||||||
| DPI-221 (Benign Prostatic Hyperplasia) |
|
||||||
| DPI-289 (Parkinson’s Disease) |
|
||||||
Want to learn more?
Read our press release go to our Investor Relations page or visit https://dmkpharma.com/
Check this page for the most recent updates regarding the merger process.